IPO - Profile

Summary

We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process.

We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 7,500,000 Positive High 12.56%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • RSM US LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jul, 2021

Offer 30 Jul, 2021

Look Ahead

Lock Up Expiry Jan 30, 2022

IPO Terms

Offer Price $15.00
Offer Size 7M

Market Sentiments

Stock Price